We present here a detailed study of the specific nanoparticle structures that give rise to single-molecule surface-enhanced Raman scattering (SMSERS). A variety of structures are observed, but the simplest are dimers of Ag nanocrystals. We chose one of these structures for detailed study using electrodynamics calculations and found that the electromagnetic SERS enhancement factors of 10(9) are easily obtained and are consistent with single-molecule SERS activity.
Numerous intestinal diseases are characterized by immune cell activation and compromised epithelial barrier function. We have shown that cytokine treatment of epithelial monolayers increases myosin II regulatory light chain (MLC) phosphorylation and decreases barrier function and that these are both reversed by MLC kinase (MLCK) inhibition. The aim of this study was to determine the mechanisms by which interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha regulate MLC phosphorylation and disrupt epithelial barrier function. We developed a model in which both cytokines were required for barrier dysfunction. Barrier dysfunction was also induced by TNF-alpha addition to IFN-gamma-primed, but not control, Caco-2 monolayers. TNF-alpha treatment of IFN-gamma-primed monolayers caused increases in both MLCK expression and MLC phosphorylation, suggesting that MLCK is a TNF-alpha-inducible protein. These effects of TNF-alpha were not mediated by nuclear factor-kappaB. However, at doses below those needed for nuclear factor-kappaB inhibition, sulfasalazine was able to prevent TNF-alpha-induced barrier dysfunction, MLCK up-regulation, and MLC phosphorylation. Low-dose sulfasalazine also prevented morphologically evident tight junction disruption induced by TNF-alpha. These data show that IFN-gamma can prime intestinal epithelial monolayers to respond to TNF-alpha by disrupting tight junction morphology and barrier function via MLCK up-regulation and MLC phosphorylation. These TNF-alpha-induced events can be prevented by the clinically relevant drug sulfasalazine.
Collagenase-3 (MMP13), a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases, is expressed in the skeleton during embryonic development and is highly overexpressed in human carcinomas and in chondrocytes and synovial cells in rheumatoid arthritis and osteoarthritis. To determine the functional roles of Mmp13, we generated Mmp13-null mice that showed profound defects in growth plate cartilage with markedly increased hypertrophic domains as well as delay in endochondral ossification and formation and vascularization of primary ossification centers. Absence of Mmp13 resulted in significant interstitial collagen accumulation due, in part, to the lack of appropriate collagenase-mediated cleavage that normally occurs in growth plates and primary ossification centers. Cartilaginous growth plate abnormalities persisted in adult mice and phenocopied defects observed in human hereditary chondrodysplasias. Our findings demonstrate a unique role of Mmp13 in skeletal development.collagen ͉ extracellular matrix ͉ vascularization C ollagenases, a group of matrix metalloproteinases (MMPs) that act at neutral pH (1-4), have been postulated to have a role in skeletal development and bone remodeling (5-8). The MMPs are members of a large family of proteinases that have several structural features in common including the presence of a conserved zinc-binding catalytic domain (1-4). Only the products of specific MMP genes, MMP1, -2, -8, -13, and -14, however, have the capacity to cleave native, undenatured, interstitial collagens at a specific helical locus (9-13). Of the collagenases, MMP13 (collagenase-3) has been considered to have an important role in skeletal biology in view of its exclusive presence in the skeleton during embryonic development in cartilaginous growth plates and primary centers of ossification (5-8). MMP13 is also a downstream target of parathyroid hormone (PTH)-related protein (PTHrP) (14) and the transcription factor Osf2͞Cbfa1͞Runx2 in growth plate chondrocytes (15,16). In contrast to humans, where MMP1 may be strongly expressed, e.g., in inflammation, the orthologue of MMP1, McolA (12), is expressed in mice only at low levels.To examine possible functional roles of collagenases during skeletal development in vivo, we targeted a null mutation to the Mmp13 gene in mice. Our targeting strategy resulted in splicing out exon 5 that encodes the zinc-binding residues in the catalytic domain. As described here, deletion of functional Mmp13 had profound effects on skeletal development. In Mmp13 Ϫ/Ϫ embryos compared with WT embryos, the growth plates were strikingly lengthened, a defect ascribable predominantly to a delay in terminal events in the growth plates, with failure to resorb collagens, as well as a delay in ossification at the primary centers. Materials and MethodsGeneration of Mmp13 ؊/؊ Mice. We isolated two Mmp13 genomic clones from a 129͞J1 library to construct the knockout vector.The first was a BamHI͞SalI fragment that spanned from Ϸ3.4 kb of promoter sequence through the first...
This study identifies and characterizes marvelD3, a novel tight junction protein that contains a conserved MARVEL domain. Analyses using phylogenetic, expression profiling, microscopic, and functional approaches show that marvelD3, occludin, and tricellulin are related and have distinct but overlapping functions at the tight junction.
Intestinal barrier function is reduced in inflammatory bowel disease (IBD). Tumor necrosis factor (TNF) and interleukin (IL)-13, which are up-regulated in IBD, induce barrier defects that are associated with myosin light chain kinase (MLCK) activation and increased claudin-2 expression, respectively, in cultured intestinal epithelial monolayers. Here we report that these independent signaling pathways have distinct effects on tight junction barrier properties and interact in vivo. MLCK activation alters size selectivity to enhance paracellular flux of uncharged macromolecules without affecting charge selectivity and can be rapidly reversed by MLCK inhibition. In contrast, IL-13-dependent claudin-2 expression increases paracellular cation flux in vitro and in vivo without altering tight junction size selectivity but is unaffected by MLCK inhibition in vitro. In vivo, MLCK activation increases paracellular flux of uncharged macromolecules and also triggers IL-13 expression, claudin-2 synthesis, and increased paracellular cation flux. We conclude that reversible, MLCK-dependent permeability increases cause mucosal immune activation that, in turn, feeds back on the tight junction to establish long-lasting barrier defects. Interactions between these otherwise distinct tight junction regulatory pathways may contribute to IBD pathogenesis.
Occludin S408 phosphorylation regulates interactions between occludin, ZO-1, and select claudins to define tight junction molecular structure and barrier function.
IFN-gamma primes intestinal epithelia to respond to TNF by inducing TNFR2 expression, which in turn mediates TNF-induced MLCK-dependent barrier dysfunction. The data further suggest that epithelial TNFR2 blockade may be a novel approach to restore barrier function in intestinal disease.
The perijunctional actomyosin ring contributes to myosin light chain kinase (MLCK)-dependent tight junction regulation. However, the specific protein interactions involved in this process are unknown. To test the hypothesis that molecular remodeling contributes to barrier regulation, tight junction protein dynamic behavior was assessed by fluorescence recovery after photobleaching (FRAP). MLCK inhibition increased barrier function and stabilized ZO-1 at the tight junction but did not affect claudin-1, occludin, or actin exchange in vitro. Pharmacologic MLCK inhibition also blocked in vivo ZO-1 exchange in wild-type, but not long MLCK −/− , mice. Conversely, ZO-1 exchange was accelerated in transgenic mice expressing constitutively active MLCK. In vitro, ZO-1 lacking the actin binding region (ABR) was not stabilized by MLCK inhibition, either in the presence or absence of endogenous ZO-1. Moreover, the free ABR interfered with full-length ZO-1 exchange and reduced basal barrier function. The free ABR also prevented increases in barrier function following MLCK inhibition in a manner that required endogenous ZO-1 expression. In silico modeling of the FRAP data suggests that tight junction-associated ZO-1 exists in three pools, two of which exchange with cytosolic ZO-1. Transport of the ABR-anchored exchangeable pool is regulated by MLCK. These data demonstrate a critical role for the ZO-1 ABR in barrier function and suggest that MLCK-dependent ZO-1 exchange is essential to this mechanism of barrier regulation.fluorescence recovery after photobleaching | mathematical models | myosin light chain kinase | paracellular permeability | intestinal epithelium G reat progress has been made toward identifying components of the tight junction. These include transmembrane, peripheral membrane, and regulatory proteins, many of which contain one or more domains that mediate interactions with other tight junction and cytoskeletal proteins (1). These and other observations drove development of models that depicted the tight junction as a static, heavily cross-linked protein complex (2). However, recent data showing rapid and continuous remodeling of the tight junction refuted the previous models and led to the hypothesis that modulation of protein remodeling behavior could be a mechanism of tight junction barrier regulation (3, 4).The perijunctional ring of F-actin and myosin II that supports the tight junction is essential to physiological and pathophysiological barrier regulation (5). For example, activation of perijunctional myosin light chain kinase (MLCK) is sufficient to enhance paracellular permeability (6, 7) and is required for tight junction barrier regulation in response to Na + -nutrient cotransport, inflammatory cytokines, or pathogenic bacteria (8). Thus, modulation of MLCK activity represents a point of convergence for multiple signaling pathways that regulate tight junction barrier function.To assess the role of molecular remodeling in barrier regulation, dynamic behaviors of tight junction proteins were assessed b...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.